Stereotaxis, Inc.
No SEC Form 4 filings for $STXS in the last 30 days.
See all $STXS insider activity →Pauls Stradiņš Clinical University Hospital in Latvia installed Stereotaxis's Genesis Robotic Magnetic Navigation System, the first of its kind in the country. The system treats cardiac arrhythmia through minimally invasive procedures. Stereotaxis (NYSE:STXS) aims to collaborate with the hospital to advance patient care and clinical science. The technology has been used to treat over 150,000 patients globally.
Stereotaxis (STXS) reported Q2 2026 revenue of $7.7M, down from $8.8M YoY due to no robotic system delivery. Robotic catheter revenue grew 270% sequentially to $1M. Recurring revenue increased to $6.2M. Gross margin was 58%. The company expects cash flow profitability by H1 2027 and guided Q3/Q4 recurring revenue at $7M and $8M, respectively. Management highlighted supply constraints and transition risks.
Stereotaxis, Inc. (STXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates ● Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially ● First GenesisX robotic system purchase by US hospital to be installed this fall ● Multiple Synchrony digi
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning STXS (Stereotaxis, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent STXS coverage spans financial news, earnings and technology.
The first robotic cardiac system in Latvia expands Stereotaxis' geographic footprint and may open a new market for future sales.
Near-term trading focus is on whether MAGiC catheter supply ramps can keep pace with demand, supporting recurring revenue guidance and eventual cash-flow profitability in 1H 2027.
The 8-K combines Q2 operating metrics with explicit Q3 and Q4 recurring and system revenue targets, plus a cash-flow profitability timeline.
The 8-K confirms deal-close equity issuance mechanics and potential future dilution via earnout-linked shares and warrants.
The article combines a fresh quarterly datapoint with a near-term supply ramp narrative and a reiterated analyst price target, supporting a bullish but execution-dependent setup.
AlphAI scores every news story that mentions STXS with an AI model for sentiment and relevance, and aggregates insider trades from Stereotaxis, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pauls Stradiņš Clinical University Hospital in Latvia installed Stereotaxis's Genesis Robotic Magnetic Navigation System, the first of its kind in the country. The system treats cardiac arrhythmia through minimally invasive procedures. Stereotaxis (NYSE:STXS) aims to collaborate with the hospital to advance patient care and clinical science. The technology has been used to treat over 150,000 patients globally.
1 min readStereotaxis (STXS) reported Q2 2026 revenue of $7.7M, down from $8.8M YoY due to no robotic system delivery. Robotic catheter revenue grew 270% sequentially to $1M. Recurring revenue increased to $6.2M. Gross margin was 58%. The company expects cash flow profitability by H1 2027 and guided Q3/Q4 recurring revenue at $7M and $8M, respectively. Management highlighted supply constraints and transition risks.
7 min readStereotaxis, Inc. (STXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates ● Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially ● First GenesisX robotic system purchase by US hospital to be installed this fall ● Multiple Synchrony digi
6 min readStereotaxis, Inc. (STXS) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. false 0001289340 0001289340 2026-07-07 2026-07-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report
3 min readStereotaxis (STXS) reported Q1 2026 revenue of $6.3M (down from $7.5M), with system revenue $1.3M and recurring revenue $5.0M. Operating loss was $6.0M; cash was $14.6M with no debt. The company cited legacy J&J catheter wind-down and said MAGiC demand exceeds supply, targeting 500 catheters/month by year-end. Citizens reiterated “Market Outperform” and a $4.00 price target.
5 min readStereotaxis (NYSE: STXS) announced its first quarter 2026 financial results and business updates, highlighting significant regulatory approvals for its MAGiC catheter and Synchrony system, and the acquisition of Robocath. While revenue for Q1 2026 was $6.3 million, down from $7.5 million in the prior year, the company anticipates double-digit revenue growth for the full year 2026, exceeding $40 million, driven by increased manufacturing and placements of its new products. Stereotaxis emphasized its strategic goal to integrate Robocath and achieve profitability without substantial investor dilution.
3 min readSurgical robotics provider Stereotaxis (STXS) reported its Q1 revenue, which fell short of analyst estimates. The news was sourced from Reuters. This brief update suggests a potential negative outlook for the company's financial performance.
3 min readStereotaxis, Inc. (STXS) saw significant regulatory milestones in Q1 2026, including FDA approvals and the acquisition agreement with Robocath. Despite a year-over-year revenue decline in Q1, the company anticipates double-digit growth for 2026 driven by increasing manufacturing capacity and the traction of new products. This information is based on an AI-generated summary of an SEC 8-K Current Report.
4 min readThe article highlights Stereotaxis, Inc. (NYSE: STXS) as one of the best robotics stocks under $30, citing its FDA-approved MAGiC catheter and recent acquisition of European robotics company Robocath. Stereotaxis's MAGiC system enables precise, computer-controlled catheter movement for minimally invasive cardiac ablation, successfully treating complex heart cases. The acquisition of Robocath is expected to provide Stereotaxis with commercial foothold in Europe and enhance its robotic surgical platform.
3 min readStereotaxis, Inc. has introduced its TeleRobotic Test Drive, enabling remote access to its RoboticEP technology for prospective clients and partners. This initiative aims to increase accessibility and adoption of robotic electrophysiology solutions. The company previously announced plans to unveil new robotic EP technology at upcoming events like EHRA2026, highlighting its focus on innovation in remote and robotic EP.
4 min read
